
Apogee Therapeutics Announces First Patient Dosed in Phase 2 APEX Trial for APG777 in Moderate to Severe Atopic Dermatitis
Enrollment of Phase 2 Part A Completed Ahead of Schedule for APG777 in Patients with AD Exciting News for Apogee Therapeutics, Inc. Apogee Therapeutics, Inc., a clinical-stage biotechnology company, has achieved a significant milestone with the completion of enrollment in the Part A portion of the Phase 2 APEX clinical trial for APG777. The trial,…